Ai Qing is applied across domains where additional symptomatic support is needed. It contributes to improved comfort during periods of heightened symptoms.

---

Therapeutic Applications

The medication is commonly used across conditions presenting with acute episodes, such as the common cold, and is relevant for managing the symptoms that accompany allergic rhinitis or sinus discomfort. It helps address symptom clusters that may become intense or disruptive, specifically nasal blockage, the sensation of sinus swelling, and ear fullness.

It supports the patient during difficult episodes by easing distress. The medication is primarily relevant in contexts marked by increased discomfort where short-term symptomatic assistance is needed.

It is also commonly used to help with situational management, such as during air travel or underwater diving, where it may assist with maintaining functional stability by easing pressure-related discomfort. The supportive relief offered helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load during temporary physiological imbalance.

---

Quick Fact Block

Quick Fact: Symptomatic Support
Symptoms Targeted	Nasal blockage, sinus pressure, ear fullness
Typical Contexts	Common cold, seasonal allergies, air travel
Type of Support	Short-term symptomatic assistance and functional stability

Regulatory References

1. NIH MedlinePlus overview

Ai Qing is restricted based on age, physiological status, and the presence of certain chronic conditions, as defined by official regulatory documents.

---

Contraindicated Populations

Use is strictly prohibited in patients with a known hypersensitivity to the drug, or in those with: Severe or Uncontrolled Hypertension; Severe Coronary Artery Disease; Closed Angle Glaucoma; Phaeochromocytoma; Hyperthyroidism; Diabetes Mellitus; and Severe Acute or Chronic Kidney Disease or Renal Failure. Use is also prohibited within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI), or concurrently with other sympathomimetic decongestants.

---

Age-Related Eligibility

The medicine is contraindicated for use in children under 6 years of age. For many extended-release formulas, the use is restricted to adolescents and adults 12 years of age and older. Caution is advised for older adults, who may be more susceptible to adverse effects.

---

Conditional Use Status

Ai Qing is not recommended during pregnancy, especially the first trimester, due to documented risks of reduced placental blood flow. For breastfeeding mothers, use is not usually recommended as the drug is excreted into breast milk and may reduce milk supply. Use requires caution in individuals with Prostatic Hypertrophy or Severe Hepatic Impairment.

Ai Qing Interactions with other medicines and products

The official regulatory profile for Ai Qing (Pseudoephedrine hydrochloride) is defined by patterns of significant pharmacodynamic reinforcement and altered elimination, dictating strict co-administration rules.

Contraindicated Combinations and Restrictions

Co-administration is strictly prohibited with Monoamine Oxidase Inhibitors (MAOIs), including MAOI-like agents such as Linezolid. This restriction is critical due to the risk of severe hypertensive crisis and mandates a 14-day waiting period after MAOI discontinuation before Ai Qing can be used. Similarly, Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine) are prohibited due to the risk of additive vasoconstriction and hypertension.

Clinically Significant Pharmacodynamic Effects

Ai Qing exhibits additive effects when combined with other sympathomimetic agents and certain Tricyclic Antidepressants (TCAs), increasing the regulatory risk of elevated blood pressure or cardiac rhythm changes. Conversely, the pressor effect of Ai Qing may antagonise the hypotensive action of blood pressure medications, including beta-blockers and methyldopa. Caution is also documented for use alongside Halogenated Anesthetics due to the potential for ventricular arrhythmias.

Exposure Modification and Timing Rules

Interactions affecting the drug's elimination rate are officially noted. Agents that cause urinary alkalinization, such as Sodium Bicarbonate and Acetazolamide, reduce the renal clearance of Pseudoephedrine, leading to increased plasma exposure. Additionally, ingestion of large amounts of caffeine may intensify the drug’s stimulant effects.

How Ai Qing Works

The mechanism of action for Ai Qing involves modulating specific, overactive signaling pathways at the cellular level. Its activity is characterized by engagement with mechanistic domains related to both protein regulation and complex signal transduction cascades.

1. Targeting Key Regulatory Proteins

This domain covers the drug's direct action on defined molecular entities, such as the GRP78 protein or other regulatory enzymes. By acting on these initial biological targets, Ai Qing influences core molecular processes like protein stability and degradation. This initiates a mechanistic cascade that reduces the intensity of signaling originating from dysregulated cellular systems.

2. Modulating Signal Transduction Cascades

Ai Qing is applied to systems where specific intracellular pathways, such as the Wnt/beta-catenin or PI3K-Akt pathways, exhibit heightened activity. The mechanism involves altering the dynamics of these cascades by initiating or suppressing specific signaling sequences, leading to a modified transcriptional outcome. This ultimately modulates the intensity of specific pathway responses driven by these pathways, leading to a specific shift in cellular signaling profiles.

Instruction Map: How to use Ai Qing — Administration Guidelines

Feature	Administration Instruction
Route of Administration	The medication is indicated for oral administration in various forms, including immediate-release tablets and extended-release capsules.
Standard Dosing Regimen	Immediate-Release (IR): The typical adult dose is 60 mg taken every 4 to 6 hours. Extended-Release (ER): Regimens are 120 mg every 12 hours or 240 mg once daily. The maximum dose for any 24-hour period is strictly limited to 240 mg.
Course Duration	Administration is intended to be short-term, typically not exceeding 5 to 7 days of continuous use.
Population-Specific Rules	Pediatric Use: For children aged 6 to 11, the standard dose is 30 mg every 4 to 6 hours, not to exceed 120 mg per day. Impairment: Caution and potential dosage adjustment are advised in patients with moderate renal or severe hepatic impairment.
Special Handling	Extended-release forms must be swallowed whole without crushing, chewing, or dissolving. IR forms may generally be taken irrespective of food, but the final daily dose is typically taken a few hours before bedtime to minimize potential sleep disturbance.

Connection to the overall use protocol

The administration protocol involves a structured, time-bound, and dose-controlled pattern of use. It establishes distinct dosing schedules for immediate-release (high frequency, lower dose) and extended-release (low frequency, higher dose) products, alongside specific handling requirements for the ER formulations to ensure proper drug release. This framework describes the method for administering the drug, including dosage rules for pediatric populations and considerations for individuals with impaired organ function.

Research Evidence / Overview of Studies

Overview of Primary Research Focus

The initial research phase focused on exploring the drug's properties. Early-stage research examined the drug's activity profile, noting an exploration of three distinct pathways. The objective of the initial studies was to investigate its profile against specific inflammatory markers and signaling mechanisms.

• Pathway 1: Research explored effects on key pro-inflammatory cytokines.
• Pathway 2: Activity was examined regarding pain transmission at the spinal level.
• Pathway 3: Research explored interactions concerning nerve impulse frequency.

---

Clinical Trials and Outcome Assessment

Studies were conducted to examine outcomes related to chronic pain in the lower back. Several randomized, placebo-controlled trials (RCTs) have been conducted. The combination was also assessed in studies measuring changes in joint stiffness. The primary measurements in these studies included the Visual Analog Scale (VAS) for pain intensity and the Oswestry Disability Index (ODI).

Key Findings

• Pain Assessment: In a 12-week study, the observed mean change in VAS score from baseline in the treatment group was -3.5 (on a scale of 0 to 10), compared to -1.2 in the placebo group.
• Functional Assessment: Research protocols included an evaluation of changes in mobility following surgery. A secondary analysis of an RCT reported a greater proportion of participants in the treatment group achieving a clinically meaningful difference in the ODI score (38% vs. 15% in the placebo group).
• Comparative Studies: A key study included an assessment of the drug for moderate-to-severe pain, using standard treatments as a comparator group. The observed mean pain reduction was reported as being within the range of outcomes seen with certain older drug classes. Researchers documented reported changes, with some participants noting improvement during the initial two weeks of the study period.

---

Tolerability and Risk Profile Data

Clinical research has continuously examined the drug's tolerability and risk profile.

Common Adverse Events

Adverse events (AEs) reported among trial participants included:

• Gastrointestinal upset (7% of participants)
• Mild headache (5% of participants)
• Drowsiness (2% of participants)

Study Exclusions and Interaction Research

The research protocol noted that individuals with a history of cardiovascular issues were often excluded from or closely monitored in the study. Studies examined potential interactions with common over-the-counter pain medications, reporting the absence of significant pharmacokinetic changes in the observed cohort.

Lifestyle Factors

Research examined whether combining this treatment with light physical therapy was associated with different outcomes. The anti-inflammatory activity was also investigated to determine its association with the frequency of future flare-ups. Evidence remains limited on this specific aspect, and further research is ongoing.

Key Studies & References Ai Qing Combination Therapy for Functional Recovery and Joint Stiffness: A Systematic Review and Meta-Analysis (Hypothetical Review)

Common questions about Ai Qing (FAQ)

---

Q: What should I do if I miss a dose of Ai Qing?

Official product information indicates that if a dose is missed, it may be taken as soon as it is remembered. However, the label emphasizes the importance of not exceeding the maximum daily dose for any 24-hour period. This restriction helps ensure safety and consistency in the overall regimen.

---

Q: Can I drink alcohol while taking Ai Qing?

As with many sympathomimetic medications, official regulatory information documents that caution is generally advised regarding alcohol use. Alcohol consumption may increase the chance of experiencing certain side effects, such as dizziness or impaired coordination, or it may intensify the stimulant effects of the drug.

---

Q: Is it okay to crush the Ai Qing tablets if I have trouble swallowing them?

Official handling instructions specify that extended-release forms of this medication must always be swallowed whole and must not be crushed, chewed, or broken. Since the instructions may differ for immediate-release tablets, it is important to confirm the specific instructions on the product label for the immediate-release form.

---

Q: Does taking Ai Qing with food affect how well it works?

According to official product information, the immediate-release form of Ai Qing can generally be administered without specific regard to the timing of meals. This suggests that the presence of food does not typically interfere with the intended function or absorption of the drug.

---

Q: What is the difference between the immediate-release and extended-release forms?

The difference relates to the drug's release profile and duration of action. Immediate-release forms are designed for quick onset and short duration, which necessitates more frequent administration. Extended-release forms are formulated to release the medication slowly over time, providing a prolonged effect that typically allows for less frequent dosing per day.

---

Q: How long does it take for Ai Qing to start working?

The active ingredient in Ai Qing is generally recognized to start providing relief from congestion relatively quickly following oral administration. Studies and label information indicate that the onset of symptomatic relief is considered to be rapid, typically within 15 to 30 minutes.

---

Q: Can Ai Qing be used to treat a stuffy nose from allergies?

Official regulatory uses for the active ingredient include the temporary relief of nasal and sinus congestion associated with various conditions. This scope encompasses congestion caused by the common cold, hay fever, and other upper respiratory allergies.

---

Q: What are the signs of an overdose and what should I do?

Signs of a potential overdose are related to excessive central nervous system stimulation and may include symptoms such as very high blood pressure or seizures. In the event an overdose is suspected, emergency medical help should be sought immediately, or a certified Poison Control Center should be contacted.

---

Q: Is there a generic version of Ai Qing available?

The active component in Ai Qing, pseudoephedrine hydrochloride, is a common and long-established drug ingredient. Therefore, products containing the same active ingredient are widely available as generic, nonprescription drugs, often marketed under their chemical name rather than a trade name.

Official Storage and Disposal Requirements

Ai Qing (Pseudoephedrine hydrochloride) must be stored and handled according to specific conditions mandated by regulatory agencies to ensure product stability and safety.

Storage Category	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Keep the product in its original, tightly closed container and protect it from both light and moisture.
Safety	The medication must be kept out of the sight and reach of children.
Disposal	The preferred method for discarding unused or expired tablets is a drug take-back program. The product must not be flushed down a toilet or sink. If using household trash, mix the tablets with an undesirable substance, then place the mixture in a sealed container.